| Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Rawcliffe Adrian | Chief Executive Officer | Sep 01 | Sale | 8.51 | 2,776 | 23,637 | 3,076 | Sep 02 09:00 PM | | TAYTON-MARTIN HELEN KATRINA | Chief Business Officer | Aug 03 | Sale | 8.74 | 200,000 | 1,748,180 | 0 | Aug 04 09:02 PM | | Lunger John | Chief Patient Supply Officer | Aug 03 | Sale | 9.25 | 4,823 | 44,613 | 8,066 | Aug 04 09:02 PM | | Rawcliffe Adrian | Chief Executive Officer | Aug 03 | Sale | 9.25 | 2,788 | 25,789 | 3,064 | Aug 04 09:01 PM | | Wood Gavin | Chief Financial Officer | Jun 29 | Buy | 1.62 | 33,000 | 53,460 | 33,000 | Jun 30 09:01 PM | | Alleva Lawrence M | Director | Jun 09 | Buy | 1.89 | 12,900 | 24,381 | 12,900 | Jun 11 09:00 PM | | Noble James | Director | May 29 | Sale | 9.33 | 500,000 | 4,666,000 | 0 | Jun 02 09:30 PM | | Sonsini Peter W. | 10% Owner | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:55 PM | | SANDELL SCOTT D | 10% Owner | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:54 PM | | Florence Anthony A. Jr. | 10% Owner | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:52 PM | | MOTT DAVID M | Director | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:53 PM | | BASKETT FOREST | 10% Owner | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:51 PM | | Behbahani Ali | Director | Jan 24 | Buy | 0.67 | 7,500,000 | 5,000,250 | 19,500,000 | Jan 28 04:52 PM | | Norry Elliot | Chief Medical Officer | Jan 14 | Sale | 5.13 | 911 | 4,678 | 1,326 | Jan 15 08:03 PM | | Bertrand William C JR | Chief Operating Officer | Jan 14 | Sale | 5.13 | 2,397 | 12,308 | 3,605 | Jan 15 08:03 PM | | Rawcliffe Adrian | Chief Executive Officer | Jan 14 | Sale | 5.13 | 3,236 | 16,616 | 3,166 | Jan 15 08:01 PM | | Lunger John | Chief Patient Supply Officer | Jan 14 | Sale | 5.13 | 1,144 | 5,874 | 1,681 | Jan 15 08:02 PM | | Noble James | Director | Jan 13 | Sale | 4.67 | 300,000 | 1,400,000 | 0 | Jan 15 08:01 PM | | TAYTON-MARTIN HELEN KATRINA | Chief Business Officer | Jan 13 | Sale | 4.50 | 100,000 | 450,000 | 0 | Jan 15 08:02 PM | | Rawcliffe Adrian | Chief Executive Officer | Jan 06 | Sale | 1.20 | 5,900 | 7,080 | 5,804 | Jan 07 08:00 PM | | Bertrand William C JR | Chief Operating Officer | Jan 06 | Sale | 1.20 | 3,731 | 4,477 | 5,632 | Jan 07 08:01 PM | | Lunger John | Chief Patient Supply Officer | Jan 06 | Sale | 1.20 | 1,148 | 1,378 | 1,677 | Jan 07 08:01 PM |
|
